Repligen Stock News

Travel stocks, oil prices and bond yields dived; Test and biotech leaders rally toward buy points.

Veriti Management LLC decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 20.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 959 shares of the biotechnology companys stock after selling 250 shares during the quarter. Veriti Management LLCs holdings in Repligen []

Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 17,355 shares of Repligen stock in a transaction dated Thursday, November 18th. The stock was sold at an average price of $276.85, for a total value of $4,804,731.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. []

Related Stocks: RGEN ,

Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 17,355 shares of Repligen stock in a transaction on Thursday, November 18th. The shares were sold at an average price of $276.85, for a total value of $4,804,731.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. []

Style Box ETF report for RFG

Analysts forecast that Repligen Co. (NASDAQ:RGEN) will report sales of $179.73 million for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Repligens earnings, with estimates ranging from $177.50 million to $181.56 million. Repligen posted sales of $108.65 million during the same quarter last year, which would indicate a positive year []

Related Stocks: RGEN , AHCO , BCYC ,

Related Stocks: RGEN , COUP , CDNS , ADSK , STNE , CP , LSPD , BL , TOST , CRL , DOCS , AFRM , AON , CNI , SQSP , BKNG , MGP , PHR ,

WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at tw

Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021.

Repligen Corporation (RGEN) CEO Anthony Hunt on Q3 2021 Results - Earnings Call Transcript

Repligen (RGEN) delivered earnings and revenue surprises of 21.88% and 8.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) beats earnings and sales estimates in the third quarter of 2021.

On Repligen's (RGEN) third-quarter earnings call, investor focus is likely to be on the sales performance of its product franchisees - filtration, chromatography, protein and process analytics.